Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial

PURPOSE: Docetaxel added to androgen-deprivation therapy (ADT) significantly increases the longevity of some patients with metastatic hormone-sensitive prostate cancer. Herein, we present the outcomes of the CHAARTED (Chemohormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Dise...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Kyriakopoulos, Christos E., Chen, Yu-Hui, Carducci, Michael A., Liu, Glenn, Jarrard, David F., Hahn, Noah M., Shevrin, Daniel H., Dreicer, Robert, Hussain, Maha, Eisenberger, Mario, Kohli, Manish, Plimack, Elizabeth R., Vogelzang, Nicholas J., Picus, Joel, Cooney, Matthew M., Garcia, Jorge A., DiPaola, Robert S., Sweeney, Christopher J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5891129/
https://ncbi.nlm.nih.gov/pubmed/29384722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.75.3657
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados